

Curriculum Vitae

Saeed Kolahian PD Dr.
d.o.b. 19.04.1981 - Tabriz, Iran

University Education

July 2020 Approbation as Veterinarian, Justus Liebig University of Gießen and Ludwig Maximilian University, Munich, Germany
June 2020 Habilitation in Experimental Pharmacology, University Hospital Tübingen, Eberhard Karls University of Tübingen, Germany
Topic: "Regulation of Airway Inflammation and Remodelling in Asthma and COPD"
2005 – 2009 Pharmacology (Ph.D.), Faculty of Veterinary Medicine, Tehran University, Iran
1999 – 2005 Veterinary Medicine (DVM), Faculty of Veterinary Medicine, Urmia University, Iran

Scientific Career

January 2024 – Present Head of Small Animal Imaging Core Facility
Center for Tumor and Immunobiology, Medical Faculty, Philipps University of Marburg
April 2021 – 2023 Research Group Leader, Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Philipps University of Marburg
2017– 2021 Academic Member and Research Group Leader, Department of Experimental and Clinical Pharmacology and Pharmacogenomics, University Hospital Tübingen
2015 – 2017 Experienced Scientist from Humboldt foundation, Children's Hospital of the University of Tübingen, Paediatric Infectiology and Immunology
2014 Visiting Professor and Scientist, Section of Pulmonary, Critical Care and Sleep Medicine, Yale school of Medicine, USA
2011 Visiting Professor and Scientist, Department of Molecular Pharmacology University of Groningen, the Netherlands
2009 – 2015 Assistant/Associate Professor in Pharmacology, Department of Basic Sciences, Faculty of Veterinary Medicine, University of Tabriz, Iran
2008 Sabbatical Leave, Department of Molecular Pharmacology, University of Groningen, the Netherlands
2011 –2015 Small Animal Clinician, Pasteur Pet Clinic, Tabriz, Iran

Current funding grants (All as main PI):

- October 2023 Stiftung für Pathobiochemie und Molekulare Diagnostik (SPMD)
Title: Role and characterization of myeloid-derived suppressor cell subsets in *Acinetobacter Iwoffii*-induced asthma tolerance (PhD student position for one and half year 100.000 Euro)
- July 2023 German Research Foundation (DFG) (PhD student position for three years 278.490 Euro)
Title: The role of prostaglandin E2 receptor 4 (EP4) on myeloid-derived suppressor cells in asthma exacerbation
- January 2022, Stiftung Pathobiochemie und Molekulare Diagnostik (PhD student position for one year 70.435 Euro)
Title: Characterizing the emergence of myeloid-derived suppressor cell subsets in pulmonary fibrosis using single-cell transcriptomics
- May 2020, University of Tübingen fortune program (PhD student position for one year 50.000 Euro)
Title: The emerging role of myeloid-derived suppressor cells in asthma exacerbation
- April 2018, University of Tübingen fortune program (PhD student position for two years 100.000 Euro)
Title: Generation and activation of myeloid-derived suppressor cells using PGE2 in asthma model
- October 2018, University of Tübingen IZKF program (in collaboration with surgery department, MD student; 12.200 Euro)
Title: The emerging role of myeloid-derived suppressor cells and macrophages, in obesity-specific immune responses to immunosuppressants in a murine model of allograft skin transplantation

Citation Record: 2375, h-Index: 15, i10-Index: 21 (Google Scholar June 24th, 2024)

Curriculum Vitae

van Geffen C, Lange T, **Kolahian S**. Myeloid-derived suppressor cells in influenza virus-induced asthma exacerbation. *Frontiers in Immunology* 2024,15:1342497.

Vetter C, Schieb J, Vedder N, Lange T, Brunn T, van Geffen C, Gercke P, **Kolahian S**. The impact of IL-10 and IL-17 on myeloid-derived suppressor cells *in vitro* and *in vivo* in a murine model of asthma. *European Journal of Immunology* 2024, 23:e2350785.

Wu F, Li X, Looso M, Liu H, Ding D, Günther S, Kuenne C, Liu S, Weissmann N, Boettger T, Atzberger A, **Kolahian S**, Renz H, Offermanns S, Gärtner U, Potente M, Zhou Y, Yuan X, Braun T. Spurious transcription causing innate immune responses is prevented by 5-hydroxymethylcytosine. *Nature Genetics* 2023, 55(1):100-111.

Cebulla D, van Geffen C, **Kolahian S**. The role of PGE2 and EP receptors on lung's immune and structural cells; possibilities for future asthma therapy. *Pharmacology & Therapeutics* 2023, 241:108313.

van Geffen C, Heiss C, Deißler A, **Kolahian S**. Pharmacological modulation of myeloid derived suppressor cells to dampen inflammation. *Frontiers in Immunology* 2022, 13:933847.

van Geffen C, Deißler A, Beer-Hammer S, Nürnberg B, Handgretinger R, Renz H, Hartl D, **Kolahian S**. Myeloid-derived suppressor cells dampen airway inflammation through prostaglandin E2 receptor 4. *Frontiers in Immunology* 2021, 12:695933.

van Geffen C, Deißler A, Quante M, Renz H, Hartl D, **Kolahian S**. Regulatory immune cells in idiopathic pulmonary fibrosis: Friends or foes? *Frontiers in Immunology* 2021, 12:663203.

Korde A, Jin L, Zhang JG, Ramaswamy A, Hu B, **Kolahian S**, Guardela BJ, Herazo-Maya J, Siegfried JM, Stabile L, Pisani MA, Herbst RS, Kaminski N, Elias JA, Puchalski JT, Takyar SS. Lung Endothelial MicroRNA-1 Regulates Tumor Growth and Angiogenesis. *American Journal of Respiratory and Critical Care Medicine* 2017, 196(11):1443-1455.

Kolahian S, Fernandez IE, Eickelberg O, Hartl D. Immune mechanisms in pulmonary fibrosis. *American Journal of Respiratory cell and Molecular Biology* 2016, 55(3): 309-322.

Kolahian S, Öz H, Zhou B, Griessinger C, Rieber N, Hartl D. The emerging role of myeloid-derived suppressor cells in lung diseases. *European Respiratory Journal* 2016, 47(3): 967-977.